Title | Soluble adenylyl cyclase antibody profile as a diagnostic adjunct in the assessment of pigmented lesions. |
Publication Type | Journal Article |
Year of Publication | 2012 |
Authors | Magro CM, A Crowson N, Desman G, Zippin JH |
Journal | Arch Dermatol |
Volume | 148 |
Issue | 3 |
Pagination | 335-44 |
Date Published | 2012 Mar |
ISSN | 1538-3652 |
Keywords | Adenylyl Cyclases, Algorithms, Biomarkers, Tumor, Cell Transformation, Neoplastic, Disease Progression, Humans, Hutchinson's Melanotic Freckle, Immunoenzyme Techniques, Lymphatic Metastasis, Melanocytes, Melanoma, Neoplasm Recurrence, Local, Neoplasm Staging, Nevus, Pigmented, Predictive Value of Tests, Skin, Skin Neoplasms |
Abstract | OBJECTIVE: To investigate the usefulness of a novel marker for melanocytic proliferations. DESIGN: Using a novel monoclonal antibody against soluble adenylyl cyclase (sAC), various benign and malignant melanocytic proliferations were immunostained. SETTING: Weill Medical College of Cornell University dermatopathology laboratory. MAIN OUTCOME MEASURES: The results were qualitative, not quantifiable. RESULTS: The sAC immunostaining produced distinctive patterns that paralleled melanomagenesis. At one pole of the spectrum were benign nevi, including atypical nevi of special sites and recurrent nevi showing a distinct pattern of dotlike Golgi staining, while at the opposite pole was melanoma, in which many cells demonstrated an intense pannuclear expression pattern, often accompanied by loss of the Golgi expression pattern. Melanomas of lentigo maligna and acral lentiginous subtypes exhibited the most striking pannuclear expression, while nodular melanomas showed the least, although with supervening enhanced diffuse cytoplasmic expression. Loss of the Golgi expression pattern was a feature of malignant melanoma. CONCLUSION: The sAC expression pattern is complex but seems discriminatory, with distinctive and variable staining patterns according to the nature of the lesion biopsied. |
DOI | 10.1001/archdermatol.2011.338 |
Alternate Journal | Arch Dermatol |
PubMed ID | 22105816 |
PubMed Central ID | PMC3387488 |
Grant List | K08 CA160657 / CA / NCI NIH HHS / United States |